JSPR Jasper Therapeutics, Inc.
USHealthcareAs of 2026-07-09 16:00
Why JSPR matters now
Jasper Therapeutics, Inc. (JSPR) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.58 with +12.98% on the session and $9.4M in market capitalization; recent performance reads 1-month -44.64% and YTD -75.25%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-1.2M, and EPS of $-0.08. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -935.5%.
The latest indexable market news headline is "Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Hold with a median target of $3.00; recent insider activity includes Mahal Jeetinder Singh filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.55
P/S
0.00
EV/EBITDA
0.11
DCF Value
$1.44
FCF Yield
-935.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-523.0%
ROA
-263.1%
ROIC
-564.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-1.2M | $-0.08 |
| Q4 2025 | $0.00 | $-9.1M | $-0.59 |
| FY 2025 | $0.00 | $-75.8M | $-3.95 |
| Q3 2025 | $0.00 | $-18.7M | $-1.13 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$3.00
Target (Median)
$3.00
Target Range
$3.00 - $3.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
3.00
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for hematopoietic stem cell transplantation and gene therapies. Its core mission is to develop and commercialize conditioning agents and advanced stem cell engineering methods. These advancements aim to expand the utility of stem cell transplantation and ex vivo gene therapy, a process involving genetic modification of cells outside the body before their transplantation. JSP191 stands as the company's leading investigational product, currently in clinical development. This conditioning antibody functions by ablating hematopoietic stem cells from patients' bone marrow as a prerequisite for allogeneic stem cell or stem cell gene therapy. Additionally, Jasper is creating engineered hematopoietic stem cell product candidates intended to address significant limitations inherent in both allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.